APLI.TOAppili Therapeutics Inc.
This is the year Appili Therapeutics has to prove it can survive — and the next catalyst is the October 15, 2026, Liquidity Resolution / Capital Raise, which will either anchor the stock at $0.01 or reset it to $0.005. The company is staring down a $13.3M debt load with just $138k in cash, and the market is already pricing in a toxic equity raise from its $0.01 base. If Appili can secure a non-dilutive biodefence grant, it could rally to $0.015, but the odds are stacked against it — with a 35% chance of a bullish outcome and a 65% chance of a bearish reset. The path forward is clear: either the company gets its liquidity fix, or it gets liquidated.
The schedule
- Thu15Oct
With just $138k in cash against $13.3M in debt, Appili must address its severe liquidity overhang. Securing a non-dilutive biodefence grant could drive shares to $0.015, but a toxic equity raise from its $0.01 base risks a reset to $0.005.
- Thu12Nov
Appili's Q2 print will focus on LIKMEZ U.S. commercial traction and cash burn. Stronger-than-expected sales growth can support a $0.01 target, whereas stalled momentum from its $0.01 base price threatens a breakdown to $0.005.
- Thu11Feb
The Q3 update will test the sustainability of the LIKMEZ commercial ramp. Demonstrable operating leverage off the $0.01 base could propel the stock to $0.015, while a top-line miss sends it to $0.005.
- Tue30Mar
Management guided toward an NDA submission pathway for TRUQUESTA. Formalizing this timeline could re-rate the stock from $0.01 to $0.02, while regulatory delays push the valuation to $0.005.
- Fri25Jun
The fiscal year-end report will solidify Appili's full-year LIKMEZ revenues and FY28 guidance. Achieving break-even or strong growth from $0.01 targets $0.02, while widening losses risk $0.005.
- Fri24Sep
- Fri24Dec
- Fri24Mar
